Intelicare Holdings Limited engages in the sale of a predictive analytics hardware and software package for use in the aged care and health industries in Australia.
Intelicare Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.10|
|52 Week High||AU$0.094|
|52 Week Low||AU$0.33|
|1 Month Change||10.53%|
|3 Month Change||-41.67%|
|1 Year Change||-64.41%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-66.67%|
Recent News & Updates
|ICR||AU Healthcare Services||AU Market|
Return vs Industry: ICR underperformed the Australian Healthcare Services industry which returned 41.1% over the past year.
Return vs Market: ICR underperformed the Australian Market which returned 21.4% over the past year.
Stable Share Price: ICR is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: ICR's weekly volatility (10%) has been stable over the past year.
About the Company
Intelicare Holdings Limited engages in the sale of a predictive analytics hardware and software package for use in the aged care and health industries in Australia. It offers InteliCare, a monitoring system; and InteliLiving for seniors and people with disability. The company was founded in 2016 and is headquartered in Leederville, Australia.
Intelicare Holdings Fundamentals Summary
|ICR fundamental statistics|
Is ICR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ICR income statement (TTM)|
|Cost of Revenue||AU$1.89m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.052|
|Net Profit Margin||-1,171.59%|
How did ICR perform over the long term?See historical performance and comparison
Is Intelicare Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ICR's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ICR's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ICR is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.
PE vs Market: ICR is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ICR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ICR is good value based on its PB Ratio (3.4x) compared to the AU Healthcare Services industry average (4.1x).
How is Intelicare Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Intelicare Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Intelicare Holdings performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ICR is currently unprofitable.
Growing Profit Margin: ICR is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ICR's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ICR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ICR is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).
Return on Equity
High ROE: ICR has a negative Return on Equity (-168.48%), as it is currently unprofitable.
How is Intelicare Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: ICR's short term assets (A$3.2M) exceed its short term liabilities (A$827.9K).
Long Term Liabilities: ICR's short term assets (A$3.2M) exceed its long term liabilities (A$14.7K).
Debt to Equity History and Analysis
Debt Level: ICR is debt free.
Reducing Debt: ICR had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ICR has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ICR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 62.2% each year
What is Intelicare Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ICR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ICR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ICR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ICR's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ICR's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Jason Waller, CSC, MMgt, BSc, GAICD, has been the Chief Executive Officer, Managing Director and a Director of Intelicare Holdings Limited since October 23, 2019. Mr. Waller served as the Chief Executi...
CEO Compensation Analysis
Compensation vs Market: Jason's total compensation ($USD345.51K) is about average for companies of similar size in the Australian market ($USD303.33K).
Compensation vs Earnings: Jason's compensation has been consistent with company performance over the past year.
Experienced Board: ICR's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.5%.
Intelicare Holdings Limited's employee growth, exchange listings and data sources
- Name: Intelicare Holdings Limited
- Ticker: ICR
- Exchange: ASX
- Founded: 2016
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$8.164m
- Shares outstanding: 84.17m
- Website: https://intelicare.com.au
- Intelicare Holdings Limited
- 299 Vincent Street
- Level 1
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/22 07:05|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.